IDEAYA Biosciences (IDYA) Capital Expenditures (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Capital Expenditures data on file, last reported at $967000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 47.86% year-over-year to $967000.0; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 231.81% YoY), and the FY2025 full-year result was $2.4 million, up 60.11% from the prior year.
• Capital Expenditures retreated to $967000.0 in Q1 2026, from $1.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.4 million in Q3 2022 to a low of -$3.1 million in Q4 2022.
• A 5-year average of $445058.8 and a median of $746000.0 in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures slumped 605.62% in 2022 and surged 766.44% in 2024, its largest moves.
• Tracing IDYA's Capital Expenditures over 5 years: stood at -$3.1 million in 2022, then jumped by 127.39% to $838000.0 in 2023, then plunged by 76.01% to $201000.0 in 2024, then jumped by 765.17% to $1.7 million in 2025, then sank by 44.39% to $967000.0 in 2026.
• Business Quant data shows IDYA's Capital Expenditures at $967000.0 in Q1 2026, $1.7 million in Q4 2025, and -$1.4 million in Q3 2025.